M&A mojo needed as big pharma sales lag drug market growth
This article was originally published in Scrip
The sales growth of big pharma companies has been lagging behind that of the global drug market since 2011, and the gap is widening. To pull back, M&A is key, but big pharma faces an uphill battle and will need to deploy its resources wisely as its firepower in the deal making marketplace is in decline relative to rival firms in the big biotech and specialty pharma space. These are the conclusions reached by Ernst & Young in a new report entitled Closing the Gap? Big Pharma's Growth Challenge and Implications for Deals.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.